A Pilot Study of Daptomycin for Antimicrobial Prophylaxis

Phase 4 Terminated 11 enrolled Duke University Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) · collab

NaSingle-groupOpen-label

Summary

The goals of the study are to evaluate the feasibility of using daptomycin as a prophylactic antimicrobial agent in patients undergoing cardiac surgery, to determine the rates of surgical site infection, and to evaluate the occurrence of adverse events.

Timeline

Start: 2008-01
Primary completion: 2008-09
Completion: 2008-09

Outcome

Outcome not reported

Stopped: “Study closed. PI left the institution.”

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Daptomycin	Other / unclassified	6 mg/kg	Intravenous

Indications

No indication recorded.